SCHEMBL5352784

SCHEMBL5352784

CCC(C(=O)O)c1ccc2ccc3cccc4ccc1c2c34.O=C1CCC(=O)N1O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
KMT2A Q03164 4/20 0.36
HPGD P15428 3/20 0.36
KDM4E B2RXH2 3/20 0.36
HSD17B10 Q99714 2/20 0.36
MEN1 O00255 2/20 0.36
CYP1A2 P05177 1/20 0.36
GLA P06280 1/20 0.36
POLB P06746 1/20 0.36
CYP2D6 P10635 1/20 0.36
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.34
PPARD Q03181 1/20 0.33
PPARA Q07869 1/20 0.33
FAAH O00519 1/20 0.33
AKR1C3 P42330 4/20 0.32
AKR1C2 P52895 4/20 0.32
HTR1A P08908 1/20 0.32
ADRA1A P35348 1/20 0.32
AKR1C1 Q04828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29439072 0.87 ALDH1A1 (0.44) ALDH1A1KMT2AHPGDKDM4EHSD17B10
SCHEMBL38870 0.87 ALDH1A1 (0.44) ALDH1A1KMT2AHPGDKDM4EHSD17B10
Succinimide SCHEMBL28533922 0.84 ALDH1A1 (0.36) ALDH1A1KMT2AHPGDKDM4EHSD17B10
SCHEMBL136158 0.80 KDM4E (0.34) ALDH1A1KMT2AHPGDKDM4EHSD17B10
SCHEMBL15881404 0.79 ALDH1A1 (0.38) ALDH1A1KMT2AHPGDKDM4EHSD17B10
SCHEMBL3485158 0.78 KMT2A (0.49) ALDH1A1KMT2AHPGDKDM4EHSD17B10
SCHEMBL16428359 0.77 ALDH1A1 (0.42) ALDH1A1KMT2AHPGDKDM4EHSD17B10
Pyrene SCHEMBL5502107 0.77 KMT2A (0.46) ALDH1A1KMT2AHPGDKDM4EHSD17B10
SCHEMBL10905515 0.76 ALDH1A1 (0.43) ALDH1A1KMT2AHPGDKDM4EHSD17B10
SCHEMBL5349813 0.76 AKR1C3 (0.35) ALDH1A1KMT2AHPGDKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11121176-B2 Nearly 2D electronic microparticles MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-09-14 US disclosed
US-20130183249-A1 Stimulus Sensitive Magnetic Nanocomposite Using Pyrene Polymer, and Contrast Medium Composition Containing the Nanocomposite INDUSTRY ACADEMIC COOPERATION FOUNDATION YOUNSEI UNIVERSITY (KR) 2013-07-18 US disclosed
US-7235650-B2 Derivatized oligonucleotides having improved uptake and other properties ISIS PHARMACEUTICALS, INC. (US) 2007-06-26 US disclosed
US-7223833-B1 Peptide nucleic acid conjugates ISIS PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-7125975-B2 Derivatized oligonucleotides having improved uptake and other properties ISIS PHARMACEUTICALS, INC. (US) 2006-10-24 US disclosed
US-7122649-B2 Derivatized oligonucleotides having improved uptake and other properties ISIS PHARMACEUTICALS, INC. (US) 2006-10-17 US disclosed
US-20050158727-A1 Derivatized oligonucleotides having improved uptake and other properties ISIS PHARMACEUTICALS, INC. 2005-07-21 US disclosed
US-6919439-B2 Derivatized oligonucleotides having improved uptake and other properties ISIS PHARMACEUTICALS, INC. (US) 2005-07-19 US disclosed
US-20050043219-A1 Derivatized oligonucleotides having improved uptake and other properties ISIS PHARMACEUTICALS, INC. 2005-02-24 US disclosed
US-6831166-B2 Nucleoside composition for use as tool in human therapeutics and diagnositcs ISIS PHARMACEUTICALS, INC. 2004-12-14 US disclosed
EP-0724447-B1 DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE ISIS PHARMACEUTICALS INC (US) 2003-05-07 EP disclosed
US-20030064492-A1 Derivatized oligonucleotides having improved uptake and other properties ISIS PHARMACEUTICALS, INC. 2003-04-03 US disclosed
US-20020177150-A1 Derivatized oligonucleotides having improved uptake and other properties ISIS PHARMACEUTICAL, INC. 2002-11-28 US disclosed
EP-0804456-B1 PEPTIDE NUCLEIC ACID CONJUGATES ISIS PHARMACEUTICALS INC (US) 2002-08-21 EP disclosed
US-6395492-B1 MONITORING CELLULAR INTAKE OF ADJUSTED NUCLEOSIDES; OBTAIN ORGANISM, INCUBATE WITH ADJUSTED NUCLEOSIDES, MONITOR CELL FOR REPORTER SIGNAL, PRESENCE INDICATES INTAKE ISIS PHARMACEUTICALS, INC. 2002-05-28 US disclosed
US-6153737-A OLIGONUCLEOTIDES HAVING IMPROVED TRANSFER ACROSS CELLULAR MEMBRANES; FOR ASSAYING DISEASE STATES IN ANIMALS; HAVING IMPROVED TRANSFER AND UPTAKE PROPERTIES FOR TREATMENT OF DISEASES THROUGH MODULATION OF ACTIVITY OF DNA AND RNA ISIS PHARMACEUTICALS, INC. (US) 2000-11-28 US disclosed
EP-0804456-A4 PEPTIDE NUCLEIC ACID CONJUGATES ISIS PHARMACEUTICALS INC (US) 1999-05-19 EP disclosed
EP-0804456-A1 PEPTIDE NUCLEIC ACID CONJUGATES ISIS PHARMACEUTICALS, INC. (US) 1997-11-05 EP disclosed
WO-1996011205-A9 PEPTIDE NUCLEIC ACID CONJUGATES 1996-05-30 WO disclosed
WO-1996011205-A1 PEPTIDE NUCLEIC ACID CONJUGATES ISIS PHARMACEUTICALS, INC. (US) 1996-04-18 WO disclosed